Frontier Biotechnologies Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Nanjing China (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2014
NCT02369965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Frontier Biotechnologies Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Back Pain (Phase 2)

HIV Infections (Phase 3)

Infections (Phase 2)

Low Back Pain (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 8